Brief: Kamada Enrolls First Patient In Trial Of CYTOGAM To Prevent CMV In Kidney Transplant Recipients
04/11/2025 12:22
Nov 4 (Reuters) - Kamada Ltd KMDA.TA: KAMADA ANNOUNCES FIRST PATIENT ENROLLED INTO AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF CYTOGAM® TO PREVENT CYTOMEGALOVIRUS IN KIDNEY TRANSPLANTATION Source text: ID:nGNXbZ3jTD Further company coverage: KMDA.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06